Literature DB >> 16859401

Drug-drug interactions involving membrane transporters in the human kidney.

Meng Li1, Gail D Anderson, Joanne Wang.   

Abstract

The kidneys play a critical role in the elimination of xenobiotics. Factors affecting the ability of the kidney to eliminate drugs may result in marked changes in the pharmacokinetics of a given compound. Drug-drug interactions due to competitive inhibition of renal organic anion or cation secretion systems have been noticed clinically for a long time. However, our understanding of the physical sites of interactions, that is, the specific transport proteins that the interacting drugs act on, has just begun very recently. This review summarises the latest progress in molecular identification and functional characterisation of major drug transporters in the human kidney. In particular, the review focuses on relating cloned renal drug transporters to clinically observed drug-drug interactions. The authors' opinion on the current status and future directions of research in these areas is also offered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16859401     DOI: 10.1517/17425255.2.4.505

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  14 in total

Review 1.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

2.  Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells.

Authors:  Li Xia; Karen Engel; Mingyan Zhou; Joanne Wang
Journal:  Am J Physiol Renal Physiol       Date:  2006-10-03

3.  Potent inhibition of human organic cation transporter 2 (hOCT2) by β-carboline alkaloids.

Authors:  David J Wagner; Haichuan Duan; Alenka Chapron; Richard W Lee; Joanne Wang
Journal:  Xenobiotica       Date:  2017-03-02       Impact factor: 1.908

4.  Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of meta-Iodobenzylguanidine (mIBG).

Authors:  Antonio J Lopez Quiñones; Leticia Salvador Vieira; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2022-02-22       Impact factor: 3.579

5.  Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.

Authors:  Jia Yin; Haichuan Duan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-10-06       Impact factor: 4.030

6.  Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity.

Authors:  Li Xia; Mingyan Zhou; Thomas F Kalhorn; Horace T B Ho; Joanne Wang
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-08

7.  Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters.

Authors:  Xiao-Yan Chu; Yuexia Liang; Xiaoxin Cai; Karla Cuevas-Licea; Ronda K Rippley; Kelem Kassahun; Magang Shou; Matthew P Braun; George A Doss; M Reza Anari; Raymond Evers
Journal:  Pharm Res       Date:  2008-12-11       Impact factor: 4.200

Review 8.  Gender differences in kidney function.

Authors:  Ivan Sabolić; Abdul R Asif; Wolfgang E Budach; Christoph Wanke; Andrew Bahn; Gerhard Burckhardt
Journal:  Pflugers Arch       Date:  2007-07-19       Impact factor: 3.657

9.  Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

Authors:  Jiwen Jim Liu; TaeWeon Lee; Ralph A DeFronzo
Journal:  Diabetes       Date:  2012-09       Impact factor: 9.461

10.  Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3.

Authors:  Ling Zou; Pär Matsson; Adrian Stecula; Huy X Ngo; Arik A Zur; Kathleen M Giacomini
Journal:  J Pharm Sci       Date:  2020-09-07       Impact factor: 3.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.